An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. [electronic resource]
Producer: 20110308Description: 337-45 p. digitalISSN:- 1529-0131
- Administration, Oral
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Aminopyridines
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- drug therapy
- Dose-Response Relationship, Drug
- Drug Resistance
- Enzyme Inhibitors -- therapeutic use
- Female
- Health Status
- Humans
- Immunologic Factors -- pharmacology
- Intracellular Signaling Peptides and Proteins -- antagonists & inhibitors
- Joints -- drug effects
- Male
- Middle Aged
- Morpholines
- Oxazines -- therapeutic use
- Prodrugs -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyridines -- therapeutic use
- Pyrimidines
- Severity of Illness Index
- Syk Kinase
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.